. Multidrug resistance and inability to completely remove invading cells during surgical resection are main contributors to poor outcomes. Here we evaluated FDA approved antibiotic nitroxoline as potential chemotherapeutic agent for glioma using MRI and genetically engineered Pten/Kras mouse model. Nitroxoline was previously shown to be effective at inhibiting growth of breast and bladder cancer xenografts in vivo 2 . In addition, nitroxoline was found to be strong inhibitor of cathepsin B, a proteinase implicated in invasive properties of many human cancers 3 . As a compound with potential to suppress glioma invasion, nitroxoline has several advantages including a long history of human use (it has been prescribed for urinary tract infections for over fifty years in Europe 2 ), minimal and tolerable side effects, and a favorable pharmacokinetic profile. , Pten/Kras in short) was generated by Dr. Wu at UCLA. Pten/Kras mice spontaneously develop grade III glioma between 10 and 12 weeks of age. Pten/Kras mice were imaged between 10 and 12 weeks to establish presence of glioma and then randomly assigned to either nitroxoline (N=6, 80 mg/kg ip. nitroxoline suspended in soybean oil) or control (N=6, 0.2 ml ip. soybean oil treatment) group. MR imaging was performed on a 7T Bruker system. A multi-echo spin echo sequence was used to quantify transverse relaxation time (T2) and for the tumor volume measurement (TR/TE 2000/7.26-101.64 ms, 14 echoes, 78 2 μm 2 resolution, 2 NAX). A diffusion-weighted echo planar imaging sequence (TR/TE 3800/22.03, with three b-value=0, 500, 1000, 3 diffusion directions and 156 2 μm 2 resolution, 2 NAX) was used to measure apparent diffusion coefficient (ADC). ADC and T2 were calculated on a pixelby pixel basis using ImageJ (plugin by Karl Schmidt). A post-contrast T1-weighted spin-echo dataset (1 mm thick slices, TR/TE 500/7.3 ms, 78 μm 2 resolution, 2 NAX) was acquired using 0.05 ml Gd-DTPA iv. injections to visualize if BBB is compromised within the tumor. At the end of the MRI studies, mice were sacrificed and tissue was processed for H&E and TUNEL-staining. TUNEL-positive cells were counted by pathologies blinded to the experimental design. A score between 0 and 4 was assigned for each section: 0 for no TUNEL-positive cells, 1: for 1-10%; 2: for 11-30%; 3: for 31-50%; and 4: for more than 50% TUNEL-positive cells. Statistical analysis was performed using paired t-test and two sample t-test for TUNEL scores, where p-value<0.05 was considered significant.
METHODS:

RESULTS:
Significant inhibition in glioma growth was observed at 7 and 14 days following nitroxoline treatment, Fig. 1 A, Fig. 2 A, in contrast to control mice that experienced doubling in tumor volumes within 14 days, Fig. 1 C, Fig. 2 
DISCUSSION:
The two most common MRI parameters used in clinical setting, T2 and ADC were measured in order to quantitatively determine treatment response profiles following nitroxoline. Since nitroxoline was mainly effective at suppressing glioma growth with ~15-20% of scattered apoptotic cells (as estimated based on TUNEL score) found upon histological examination, it is likely that this was not enough to cause change in T2. In contrast, changes in ADC-values are more sensitive to alterations in cell density, and a small, but significant increase in ADC found after 14 days of nitroxoline treatment likely reflects slightly reduced cell density due to nitroxoline induced apoptosis. These findings taken together with documented history of clinical use as antimicrobial agent, makes nitroxoline a very good candidate for clinical trials for anti-glioma therapy. (2014) 1135.
